Serum Antibodies and Prostate Cancer Risk
Author Information
Author(s): Hrbacek Jan, Urban Michael, Hamsikova Eva, Tachezy Ruth, Eis Vaclav, Brabec Marek, Heracek Jiri
Primary Institution: Charles University in Prague, 3rd Faculty of Medicine
Hypothesis
Elevated serum antibody levels or higher seroprevalence in PCa patients would suggest an association of genitourinary infection in patient history and elevated PCa risk.
Conclusion
The presence or higher levels of serum antibodies against the genitourinary pathogens studied were not consistently associated with prostate cancer.
Supporting Evidence
- PCa patients had higher seroprevalence of Ureaplasma urealyticum antibodies.
- BPH patients had higher seropositivity for HPV 18 and Chlamydia trachomatis.
- Mean serum CMV antibody levels were higher in BPH than in PCa patients.
- HPV 6 antibodies were associated with a higher Gleason score in PCa patients.
Takeaway
This study looked at whether infections could cause prostate cancer by checking blood for antibodies. It found that most infections didn't seem to increase the risk of prostate cancer.
Methodology
A case-control study comparing serum antibodies in 329 prostate cancer patients and 105 benign prostate hyperplasia controls using various serological tests.
Potential Biases
Using BPH patients as controls may not provide a meaningful conclusion if both conditions share a common etiology.
Limitations
Blood samples were drawn after the diagnosis of PCa, which does not clarify whether infection preceded or followed cancer development.
Participant Demographics
434 Caucasian males, mean age 64 years for PCa patients and 72 years for BPH controls.
Statistical Information
P-Value
0.0004
Confidence Interval
95% CI 1.08-4.28
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website